![]() ![]() The following entry encouraged me that Eikon had not just been abandoned:Ĭo-Diagnostics CEO Dwight Egan and Dr. What became of Eikon? I googled "Co-Diagnostics Eikon" on as I write. My appetite having been thoroughly whetted by previous discussions, an Eikon update was the first thing I looked for in the Call when it was released on. The Call dropped all mention of Eikon, raising questions safe schools, safe workplaces, restaurants, hotels, ships, entertainment venues. The Eikon platform goal was to provide fast, cheap and accurate results, initially for Covid-19 with multiplexing potential to extend its coverage.Ĭo-Diagnostics anticipated Eikon having a role in: Here was a versatile testing solution that fit into a broad array of testing scenarios.Įikon had featured prominently (23 hits for the word "Eikon") in Co-Diagnostics' Q3 earnings call. Wainwright presentation ()Įikon would provide an excellent encore for Co-Diagnostics to succeed as COVID-19 moved from its pandemic to an endemic phase. It included the following Eikon specifications slide:Įikon specification slide from H. This was the issue I addressed in Fences, where I enthused about Co-Diagnostics' newest product, its Eikon testing platform. ![]() The challenge for Co-Diagnostics was to maintain its mojo if and when the pandemic wound down, as indeed it currently seems to be doing. This early success catapulted it to its A+ quant ratings. As discussed in A+ Student it was at the forefront in terms of approval for its COVID-19 testing technology. Co-Diagnostics developed Eikon testing platform as a bridge to endemic COVIDĬo-Diagnostics was an effective COVID-19 testing pioneer. I am less so after reviewing its recently released Q4 2021 earnings call (the "Call") as I will explain. I have been optimistic on the company's prospects. The first was 03/2021's "Co-Diagnostics: A+ Student Faces New Tests" ("A+ Student") I followed it with 01/2022's "Co-Diagnostics: Swinging For The Fences" ("Fences"). I wrote a pair of articles to check out the fundamental story backing up its fine financial metrics. Co-Diagnostics ( NASDAQ: CODX) initially drew my attention because of its stellar A+ quant ratings. ![]()
0 Comments
Leave a Reply. |